lung cancer

News

AstraZeneca’s volrustomig hits Phase 3 setback in lung cance...

In another blow to its late-stage pipeline, AstraZeneca has pulled the plug on a phase 3 trial of its lung cancer treatment volrustomig.

Oncology

EGFR-mutant lung cancer: Cracking the drug resistance code

Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade.

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

Patients

The hidden access gap in Europe’s lung cancer hospital data

New hospital-level analysis shows a provider landscape that is more concentrated, regionally uneven & strategically complex than commercially assumed.

News

Jazz, Roche combo cleared by FDA for lung cancer

Can FDA approval of Jazz Pharma's Zepzelca in a combination regimen for extensive-stage small cell lung cancer return sales of the drug to growth?

News

Mixed data from lung cancer trials on show at WCLC

Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.

AstraZeneca’s volrustomig hits Phase 3 setback in lung cance...

EGFR-mutant lung cancer: Cracking the drug resistance code

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

The hidden access gap in Europe’s lung cancer hospital data

Jazz, Roche combo cleared by FDA for lung cancer

Mixed data from lung cancer trials on show at WCLC

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

lung cancer

Editor's Picks